Clinical Research Directory
Browse clinical research sites, groups, and studies.
Inhaled Ciclesonide Study in Preterm Infants
Sponsor: Venkatesh Sampath
Summary
Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).
Official title: The Safety and Toxicity of Inhaled Ciclesonide (i.e., Alvesco) in Preterm Infants at Risk for Developing Bronchopulmonary Dysplasia
Key Details
Gender
All
Age Range
8 Days - 35 Days
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-09-16
Completion Date
2026-08-31
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Alvesco Inhalant Product
Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.
Locations (1)
Children's Mercy Kansas City
Kansas City, Missouri, United States